PURE Bioscience, Inc. PURE, the creator of the patented silver
dihydrogen citrate (SDC) antimicrobial, today announced it has regained
compliance with Nasdaq listing requirements, and will continue trading on the
Nasdaq Capital Market.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
